{"url":"https://lda.senate.gov/api/v1/filings/577bceb9-e306-4077-8615-9644e3bb4c32/","filing_uuid":"577bceb9-e306-4077-8615-9644e3bb4c32","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2017,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/577bceb9-e306-4077-8615-9644e3bb4c32/print/","filing_document_content_type":"text/html","income":null,"expenses":"860000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Robert Lively","dt_posted":"2017-10-19T22:32:04.420000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"500 North Capitol St., NW","registrant_address_2":"Suite 330","registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":63837,"url":"https://lda.senate.gov/api/v1/registrants/63837/","house_registrant_id":35518,"name":"ALLERGAN USA, INC.","description":"Pharmaceutical development and manufacturing","address_1":"500 North Capitol St., NW","address_2":"Suite 330","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT W. LIVELY","contact_telephone":"+1 202-550-2360","dt_updated":"2022-04-06T16:06:36.149726-04:00"},"client":{"id":162336,"url":"https://lda.senate.gov/api/v1/clients/162336/","client_id":12,"name":"ALLERGAN USA, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-30"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines.\nStrategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues.\nImproving coverage and reimbursement for treatments to enhance the lives of patients.\nReimbursements to help those affected by antibiotic resistant diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Medicare and Medicaid reimbursement provisions.\nAligning reimbursements to allow patient access to critical medical treatments.\nFood and Drug Administration appropriations.\nContinuing oversight of the integrity of the pharmaceutical supply chain.  \nEnsuring the integrity of the Drug Quality and Security Act (H.R. 3204).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy including changes to corporate tax structure.\nTax codes that ensure investment in research & development of novel treatments for patients.","foreign_entity_issues":"Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent that policy affects the tax treatment of its subsidiaries, foreign and domestic.","lobbyists":[{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property protections for novel therapies to treat crucial medical needs.\nPatent reform proposals.  \nHatch-Waxman Implications of the Inter Partes Review Process.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Ensuring the safety of the drug supply chain to protect patients and keep Americans safe.\nDrug Compounding and the Drug Quality and Security Act of 2013\nDrug Importation/Counterfeit Drugs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Ensuring drug safety and efficacy gold standards at appropriate regulatory agency.\nBioequivalence issues with non-biologic complex drugs. \nProtecting patients from illegally diverted/counterfeited medicines.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Access to appropriate mental health care treatments across the U.S.\nCreating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus.  \nSupporting investment in safe, quality, accessible, and affordable biopharma products.\nEnsuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63492,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"W.","last_name":"LIVELY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61422,"prefix":null,"prefix_display":null,"first_name":"BRENT","nickname":null,"middle_name":"J","last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}